Sustainable Packaging: SGD Pharma to Lead the Decarbonisation of the Glass Industry - Interview with CEO Olivier Rousseau

“We want to be the leader in decarbonisation of the glass industry.” says Olivier Rousseau, Chief Executive Officer of SGD Pharma.
SGD Pharma is a worldwide manufacturer of molded and tubular glass for pharmaceutical primary packaging, producing 8 million vials and bottles per day.
In the latest episode of the PharmaSource podcast, Olivier sets out the company's plans for 2024 and explains how the whole company is now lazer-focused on being the most sustainable in the industry.

“2024 will be a full year of innovation” says Olivier. “We are on a growth path” with new partnerships and facilities being announced to join its existing global infrastructure of five ISO 15378 certified GMP compliant manufacturing plants.

SGD Pharma's Decarbonisation Strategy

Decarbonisation is now the company's top priority, explains Olivier.

"Our goal is to clearly lead the pharmaceutical glass primary packaging industry. We truly believe that more drug manufacturers will look to carbon levels and sustainability strategies to choose their suppliers."

"We had the ambition of reducing our CO2 emissions by 35% by 2021, and now we are working towards reducing them by 65% by 2040." he says.

“We are investing significantly in the decarbonisation of all our industrial processes and working with customers and partners across the full value chain to uncover scope one, scope two and scope three emissions to get to our goal."

Some of the decarbonisation initiatives for SGD Pharma include:

1. Hybrid furnaces

2. Re-designing industrial processes

3. Collaborating on lighter products

4. Working across the full value chain

Read the full article